James D Otvos1, John R Guyton2, Margery A Connelly1, Sydney Akapame3, Vera Bittner4, Steven L Kopecky5, Megan Lacy3, Santica M Marcovina6, Joseph B Muhlestein7, William E Boden8. 1. Laboratory Corporation of America(®) Holdings (LabCorp), Morrisville, NC, USA. 2. Department of Medicine, Duke University Medical Center, Durham, NC, USA. Electronic address: john.guyton@duke.edu. 3. Axio Research, Seattle, WA, USA. 4. Department of Cardiology, Prevention and Imaging, University of Alabama, Birmingham, AL, USA. 5. Mayo Clinic, Rochester, MN, USA. 6. Department of Medicine, University of Washington, Seattle, WA, USA. 7. Intermountain Medical Center, Murray, UT, USA; University of Utah, Salt Lake City, UT, USA. 8. VA New England Healthcare System, Bedford, MA, USA; Massachusetts Veterans Epidemiology, Research, and Informatics Center (MAVERIC), and Boston University School of Medicine, Boston, MA, USA.
Abstract
BACKGROUND: The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial showed no incremental benefit of extended-release niacin (ERN) therapy added to simvastatin in subjects with cardiovascular disease (CVD). OBJECTIVES: To examine the effects of ERN treatment on lipoprotein particles and GlycA, a new marker of systemic inflammation, and their relations with incident CVD events including mortality. METHODS: GlycA and very low-density lipoprotein, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) particle subclasses were quantified by nuclear magnetic resonance spectroscopy using available stored baseline (n = 2754) and 1-year in-trial (n = 2581) samples. Associations with CVD events and all-cause mortality were assessed using multivariable Cox proportional hazards regression adjusted for age, sex, diabetes, treatment assignment, and lipoproteins. RESULTS: Compared to placebo, ERN treatment lowered very low-density lipoprotein and LDL and increased HDL particle concentrations, increased LDL and HDL particle sizes (all P < .0001), but did not affect GlycA. Baseline and in-trial GlycA levels were associated with increased risk of CVD events: hazard ratio (HR) per SD increment, 1.17 (95% confidence interval [CI], 1.06-1.28) and 1.13 (1.02-1.26), respectively. However, none of the lipoprotein particle classes or subclasses was associated with incident CVD. By contrast, all-cause mortality was significantly associated with both GlycA (baseline HR: 1.46 [1.22-1.75]; in-trial HR: 1.41 [1.24-1.60]) and low levels of small HDL particles (baseline HR: 0.69 [0.56-0.86]; in-trial HR: 0.69 [0.56-0.86]). CONCLUSIONS: This Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial post hoc substudy indicates that inflammation, as indexed by GlycA, is unaffected by ERN treatment but is significantly associated with the residual risk of CVD and death in patients treated to low levels of LDL cholesterol.
RCT Entities:
BACKGROUND: The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial showed no incremental benefit of extended-release niacin (ERN) therapy added to simvastatin in subjects with cardiovascular disease (CVD). OBJECTIVES: To examine the effects of ERN treatment on lipoprotein particles and GlycA, a new marker of systemic inflammation, and their relations with incident CVD events including mortality. METHODS:GlycA and very low-density lipoprotein, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) particle subclasses were quantified by nuclear magnetic resonance spectroscopy using available stored baseline (n = 2754) and 1-year in-trial (n = 2581) samples. Associations with CVD events and all-cause mortality were assessed using multivariable Cox proportional hazards regression adjusted for age, sex, diabetes, treatment assignment, and lipoproteins. RESULTS: Compared to placebo, ERN treatment lowered very low-density lipoprotein and LDL and increased HDL particle concentrations, increased LDL and HDL particle sizes (all P < .0001), but did not affect GlycA. Baseline and in-trial GlycA levels were associated with increased risk of CVD events: hazard ratio (HR) per SD increment, 1.17 (95% confidence interval [CI], 1.06-1.28) and 1.13 (1.02-1.26), respectively. However, none of the lipoprotein particle classes or subclasses was associated with incident CVD. By contrast, all-cause mortality was significantly associated with both GlycA (baseline HR: 1.46 [1.22-1.75]; in-trial HR: 1.41 [1.24-1.60]) and low levels of small HDL particles (baseline HR: 0.69 [0.56-0.86]; in-trial HR: 0.69 [0.56-0.86]). CONCLUSIONS: This Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial post hoc substudy indicates that inflammation, as indexed by GlycA, is unaffected by ERN treatment but is significantly associated with the residual risk of CVD and death in patients treated to low levels of LDL cholesterol.
Authors: Robert W McGarrah; Jacob P Kelly; Damian M Craig; Carol Haynes; Ryan C Jessee; Kim M Huffman; William E Kraus; Svati H Shah Journal: Clin Chem Date: 2016-11-03 Impact factor: 8.327
Authors: William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub Journal: N Engl J Med Date: 2011-11-15 Impact factor: 91.245
Authors: James D Otvos; Irina Shalaurova; Justyna Wolak-Dinsmore; Margery A Connelly; Rachel H Mackey; James H Stein; Russell P Tracy Journal: Clin Chem Date: 2015-03-16 Impact factor: 8.327
Authors: Eke G Gruppen; Ineke J Riphagen; Margery A Connelly; James D Otvos; Stephan J L Bakker; Robin P F Dullaart Journal: PLoS One Date: 2015-09-23 Impact factor: 3.240
Authors: Micah L Olson; Ana Rentería-Mexía; Margery A Connelly; Sonia Vega-López; Erica G Soltero; Yolanda P Konopken; Allison N Williams; Felipe G Castro; Colleen S Keller; Hongwei P Yang; Michael W Todd; Gabriel Q Shaibi Journal: J Clin Lipidol Date: 2018-09-22 Impact factor: 4.766
Authors: E G Gruppen; S K Kunutsor; L M Kieneker; B van der Vegt; M A Connelly; G H de Bock; R T Gansevoort; S J L Bakker; R P F Dullaart Journal: J Intern Med Date: 2019-07-24 Impact factor: 8.989
Authors: Kayla A Riggs; Parag H Joshi; Amit Khera; James D Otvos; Philip Greenland; Colby R Ayers; Anand Rohatgi Journal: Am J Prev Cardiol Date: 2022-08-22